Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $7,004 | $12,445 | $30,018 |
| Short-Term Investments | – | $0 | $0 | $0 |
| Receivables | – | $380 | $1,259 | $2,340 |
| Inventory | – | $0 | $0 | $0 |
| Other Curr. Assets | – | $3,737 | $1,121 | $1,934 |
| Total Curr. Assets | – | $11,121 | $14,825 | $34,292 |
| Property Plant & Equip (Net) | – | $1,830 | $309 | $3,248 |
| Goodwill | – | $342 | $0 | $883 |
| Intangibles | – | $48 | $864 | $35,285 |
| Long-Term Investments | – | $0 | $0 | $2,209 |
| Tax Assets | – | $0 | $0 | -$2,209 |
| Other NC Assets | – | $2,941 | $3,718 | $6,235 |
| Total NC Assets | – | $5,161 | $4,891 | $45,651 |
| Other Assets | – | $0 | $0 | $0 |
| Total Assets | – | $16,282 | $19,716 | $79,943 |
| Liabilities | – | – | – | – |
| Payables | – | $1,243 | $4,752 | $6,611 |
| Short-Term Debt | – | $156 | $137 | $902 |
| Tax Payable | – | $0 | $0 | $0 |
| Deferred Revenue | – | $0 | $1,326 | $1,458 |
| Other Curr. Liab. | – | $1,533 | $5,537 | $6,314 |
| Total Curr. Liab. | – | $2,932 | $10,426 | $13,827 |
| LT Debt | – | $902 | $118 | $1,730 |
| Deferred Rev, NC | – | $0 | $4,584 | $5,851 |
| Deferred Tax Liab, NC | – | $0 | $0 | $14,732 |
| Other NC Liab. | – | $6,144 | $271 | $164 |
| Total NC Liab. | – | $7,046 | $4,973 | $22,477 |
| Other Liabilities | – | $0 | $0 | $0 |
| Cap. Leases | – | $1,058 | $255 | $2,632 |
| Total Liabilities | – | $9,978 | $15,399 | $36,304 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | $0 | $0 |
| Common Stock | – | $32,949 | $78,585 | $78,585 |
| Retained Earnings | – | -$358,372 | -$349,947 | -$308,997 |
| AOCI | – | $331,727 | $269,362 | $267,734 |
| Other Equity | – | $0 | $6,317 | $6,317 |
| Total Equity | – | $6,304 | $4,317 | $43,639 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | – | $16,282 | $19,716 | $79,943 |
| Net Debt | $0 | -$5,946 | -$12,190 | -$27,386 |